AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16395181 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual examination items
Number of subjects: 123
Study 16395181 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralization/peripheralization judgments with repeated or sustained extension or aberrant movement judgments
Number of subjects: 123
Study 12737671 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low-dose oral contraceptives (specific types not detailed)
Number of subjects: 227
Study 10709162 — intervention group
Group type: EXPERIMENTAL
Intervention: 201 mg fenofibrate + 40 mg pravastatin
Number of subjects: 23
Study 10709162 — intervention group
Group type: COMPARATOR
Intervention: 201 mg fenofibrate alone
Number of subjects: 23
Study 10709162 — intervention group
Group type: COMPARATOR
Intervention: 40 mg pravastatin alone
Number of subjects: 23
Study 9360431 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ceftriaxone (2 g intravenous prior to surgery)
Number of subjects: 160
Study 9360431 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose cefuroxime (1.5 g intravenous prior to surgery and 750 mg intramuscular every 8 hours for 48 hours)
Number of subjects: 160
Study 1570370 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomethiazol
Number of subjects: 41
Study 1570370 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate
Number of subjects: 41
Study 3882679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 51
Study 3882679 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 51
Study 31365624 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (75g dissolved in 200 mL of mineral water)
Number of subjects: 16
Study 31365624 — intervention group
Group type: COMPARATOR
Intervention: Glucose (75g dissolved in 200 mL of mineral water)
Number of subjects: 16
Study 29383375 — intervention group
Group type: EXPERIMENTAL
Intervention: First irrigation tested
Number of subjects: 15
Study 29383375 — intervention group
Group type: EXPERIMENTAL
Intervention: Other 3 irrigations
Number of subjects: 15
Study 29383375 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 possible order combinations
Number of subjects: 15
Study 29383375 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 order conditions based on the first irrigation
Number of subjects: 15
Study 26194449 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training skill competency intervention
Number of subjects: 361
Study 26194449 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 361
Study 25453517 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine formula (HMG)
Number of subjects: 80
Study 25453517 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (LG)
Number of subjects: 80
Study 25453517 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine formula combined with lactulose (HMCLG)
Number of subjects: 80
Study 25453517 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 80
Study 21983842 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein
Number of subjects: 101
Study 21983842 — intervention group
Group type: EXPERIMENTAL
Intervention: Desarda
Number of subjects: 101
Study 20933321 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA3 score ≥ 100
Number of subjects: 0
Study 20933321 — intervention group
Group type: COMPARATOR
Intervention: PCA3 score < 100
Number of subjects: 0
Study 20933321 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PCA3 ≥ 100
Number of subjects: 0
Study 18226744 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Trials (RCTs)
Number of subjects: 48
Study 18226744 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized Studies (NRSs)
Number of subjects: 48
Study 15982122 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary running
Number of subjects: 116
Study 15982122 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking to a target
Number of subjects: 116
Study 15982122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sidestepping at test
Number of subjects: 116
Study 15982122 — intervention group
Group type: COMPARATOR
Intervention: Eyes open during treadmill adaptation
Number of subjects: 116
Study 11871742 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat content nutrient formula (ED group) with 3.4 g of fat per 2000-kcal dose
Number of subjects: 36
Study 11871742 — intervention group
Group type: EXPERIMENTAL
Intervention: High amount of medium-chain triglycerides nutrient formula (TL group) with 55.6 g of fat per 2000-kcal dose
Number of subjects: 36
Study 11092663 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (10‐min intravenous bolus of 3, 6, 12, 24 or 36 microg/kg, followed by a 24‐h infusion of 0.05, 0.1, 0.2, 0.4 or 0.6 microg/kg/min)
Number of subjects: 151
Study 11092663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 11092663 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (open‐label infusion of 6 microg/kg/min)
Number of subjects: 151
Study 11092663 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 151
Study 8810934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (200 IU kg‐1) given as a once‐daily subcutaneous injection
Number of subjects: 330
Study 8810934 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) aPTT adjusted i.v. infusion for 6 to 10 days
Number of subjects: 330
Study 8810934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 330
Study 8810934 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 330
Study 1412723 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 (5 mg/day) for the first 14 postoperative days
Number of subjects: 108
Study 1412723 — intervention group
Group type: COMPARATOR
Intervention: CsA from the first postoperative day
Number of subjects: 108
Study 1412723 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 108
Study 1412723 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 108
Study 4096744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (750 mg/d)
Number of subjects: 10
Study 4096744 — intervention group
Group type: COMPARATOR
Intervention: Nicotinate (control)
Number of subjects: 10
Study 31243481 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg L-DOPA
Number of subjects: 111
Study 31243481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 30022253 — intervention group
Group type: EXPERIMENTAL
Intervention: TBS assessment in men
Number of subjects: 672
Study 30022253 — intervention group
Group type: EXPERIMENTAL
Intervention: TBS assessment in relation to BMI
Number of subjects: 672
Study 30022253 — intervention group
Group type: EXPERIMENTAL
Intervention: TBS assessment in relation to age
Number of subjects: 672
Study 30022253 — intervention group
Group type: EXPERIMENTAL
Intervention: TBS assessment in relation to diabetes
Number of subjects: 672
Study 30022253 — intervention group
Group type: EXPERIMENTAL
Intervention: TBS assessment in relation to SSRI use
Number of subjects: 672
Study 30022253 — intervention group
Group type: EXPERIMENTAL
Intervention: TBS assessment in relation to alcohol intake
Number of subjects: 672
Study 30022253 — intervention group
Group type: EXPERIMENTAL
Intervention: TBS assessment in relation to history of fragility fractures
Number of subjects: 672
Study 26584888 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiGeneAngio (MGA) - a single intra-arterial infusion of transduced autologous venous smooth muscle cells expressing VEGF165 and endothelial cells expressing Ang-1 (Cohort 1: 1 × 10^7, Cohort 2: 2 × 10^7, Cohort 3: 5 × 10^7, Cohort 4: 7 × 10^7)
Number of subjects: 12
Study 25342956 — intervention group
Group type: EXPERIMENTAL
Intervention: Philani Intervention Program (home visits by trained, paraprofessional community health workers)
Number of subjects: 1238
Study 25342956 — intervention group
Group type: COMPARATOR
Intervention: Control condition (comprehensive healthcare at community primary health care clinics)
Number of subjects: 1238
Study 25342956 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control conditions
Number of subjects: 1238
Study 22434783 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly, school-based, 10-min jumping regime
Number of subjects: 99
Study 22434783 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly, school-based, 10-min jumping regime (boys)
Number of subjects: 99
Study 22434783 — intervention group
Group type: COMPARATOR
Intervention: Regular PE warm-up
Number of subjects: 99
Study 20379190 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg/day)
Number of subjects: 340
Study 18807310 — intervention group
Group type: EXPERIMENTAL
Intervention: General medical journals
Number of subjects: 151
Study 18807310 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials published in 2005
Number of subjects: 151
Study 18807310 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reporting of CONSORT items
Number of subjects: 151
Study 18807310 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical Issues reporting
Number of subjects: 151
Study 18807310 — intervention group
Group type: EXPERIMENTAL
Intervention: Funding and conflicts of interest declaration
Number of subjects: 151
Study 15616239 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 1,000 mg/day t.i.d.
Number of subjects: 1257
Study 15616239 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 500 mg/day t.i.d.
Number of subjects: 1257
Study 15616239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1257
Study 12579174 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction group (n = 80) received 4 L min(‐1) O(2) with nasal cannula and expired air was aspired with a Y‐piece suction system
Number of subjects: 160
Study 12579174 — intervention group
Group type: COMPARATOR
Intervention: Non-suction group (n = 80) received 4 L min(‐1) O(2) with nasal cannula
Number of subjects: 160
Study 10687256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg daily for 2 years)
Number of subjects: 107
Study 10687256 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no pentoxifylline)
Number of subjects: 107
Study 9590776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulperazon
Number of subjects: 67
Study 9590776 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 67
Study 29562597 — intervention group
Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 334
Study 29562597 — intervention group
Group type: COMPARATOR
Intervention: Fruits and vegetables (F&V) diet
Number of subjects: 334
Study 29562597 — intervention group
Group type: EXPERIMENTAL
Intervention: Control diet
Number of subjects: 334
Study 26508436 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic packing (PACK)
Number of subjects: 56
Study 26508436 — intervention group
Group type: COMPARATOR
Intervention: Angioembolization (ANGIO)
Number of subjects: 56
Study 25248910 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led, community-based, stroke prevention self‐management group workshop (6 weeks, 1 session/week)
Number of subjects: 600
Study 25248910 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 600
Study 22784842 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (3 g daily)
Number of subjects: 66
Study 19404692 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mg sustained‐release clotrimazole varnish
Number of subjects: 14
Study 19404692 — intervention group
Group type: COMPARATOR
Intervention: 10‐mg clotrimazole oral troche
Number of subjects: 14
Study 18225447 — intervention group
Group type: EXPERIMENTAL
Intervention: CB1 antagonists; specific dosage and duration not available
Number of subjects: 0
Study 15795534 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-activated factor X (anti-FXa) assay
Number of subjects: 46
Study 15795534 — intervention group
Group type: COMPARATOR
Intervention: activated partial thromboplastin time (aPTT) assay
Number of subjects: 46
Study 12038874 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 12038874 — intervention group
Group type: EXPERIMENTAL
Intervention: Short- and long-term inhaled bronchodilators
Number of subjects: 0
Study 12038874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (cromolyn sodium)
Number of subjects: 0
Study 12038874 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophyllines (intravenous and oral)
Number of subjects: 0
Study 12038874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 12038874 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolide antibiotics
Number of subjects: 0
Study 12038874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin, cyclosporine, leukotriene antagonists
Number of subjects: 0
Study 9794853 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug interventions
Number of subjects: 364
Study 9794853 — intervention group
Group type: EXPERIMENTAL
Intervention: Established quality of life instruments
Number of subjects: 364
Study 9794853 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed measures
Number of subjects: 364
Study 9794853 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclear methods
Number of subjects: 364
Study 9794853 — intervention group
Group type: EXPERIMENTAL
Intervention: Response rates
Number of subjects: 364
Study 9794853 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete reporting
Number of subjects: 364
Study 8904473 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 800 mg/kg/day for 3 days plus phototherapy
Number of subjects: 40
Study 8904473 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy only
Number of subjects: 40
Study 2694046 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacle lenses with prism
Number of subjects: 0
Study 2694046 — intervention group
Group type: COMPARATOR
Intervention: Control group (without prism)
Number of subjects: 0
Study 739228 — intervention group
Group type: EXPERIMENTAL
Intervention: Guthion-treated plot
Number of subjects: 15
Study 739228 — intervention group
Group type: COMPARATOR
Intervention: Control plot
Number of subjects: 15
Study 31046493 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal plants used in the treatment of kidney stones
Number of subjects: 0
Study 31046493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effective management options
Number of subjects: 0
Study 28438147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy
Number of subjects: 501
Study 28438147 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (mostly cognitive-based therapy)
Number of subjects: 501
Study 28438147 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with depression, anxiety, stress, and adjustment disorders
Number of subjects: 501
Study 28438147 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 501
Study 25555830 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized complementary medicine (CM group)
Number of subjects: 275
Study 25555830 — intervention group
Group type: COMPARATOR
Intervention: Usual care (usual care group)
Number of subjects: 275
Study 25555830 — intervention group
Group type: COMPARATOR
Intervention: Comparison between CM group and usual care group
Number of subjects: 275
Study 24303433 — intervention group
Group type: EXPERIMENTAL
Intervention: 4ml of solution containing 1:200000 adrenaline and 2mg/kg tramadol injected in peritonsillar space (Group A)
Number of subjects: 46
Study 24303433 — intervention group
Group type: COMPARATOR
Intervention: 4ml of normal saline injected in peritonsillar space (Group B)
Number of subjects: 46
Study 21716117 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic analgesia with sublingual tramadol Hcl (50 mg) and oral lorazepam (1 mg)
Number of subjects: 113
Study 21716117 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam (5 mg) alone
Number of subjects: 113
Study 19247187 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg pretreatment
Number of subjects: 105
Study 19247187 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg pretreatment with statin therapy
Number of subjects: 105
Study 19247187 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg pretreatment in patients with diabetes
Number of subjects: 105
Study 19247187 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg pretreatment in tobacco smokers
Number of subjects: 105
Study 16490846 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS)
Number of subjects: 408
Study 16490846 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision
Number of subjects: 408
Study 12766921 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 66
Study 12766921 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 66
Study 10694560 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PeCT) - fluorouracil, doxorubicin, and cyclophosphamide
Number of subjects: 0
Study 10694560 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 0
Study 9366939 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolled gauze swabs
Number of subjects: 120
Study 9366939 — intervention group
Group type: COMPARATOR
Intervention: Guedel airway
Number of subjects: 120
Study 8251962 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational statements
Number of subjects: 27
Study 8251962 — intervention group
Group type: COMPARATOR
Intervention: Irrational statements
Number of subjects: 27
Study 3005801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol administration after a midnight dose of metyrapone (30 mg/kg)
Number of subjects: 24
Study 31870463 — intervention group
Group type: EXPERIMENTAL
Intervention: EMIQ® (2 mg aglycone equivalent)/kg body weight
Number of subjects: 25
Study 31870463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 28143667 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet supplemented with extra-virgin olive oil
Number of subjects: 870
Study 28143667 — intervention group
Group type: COMPARATOR
Intervention: MedDiet supplemented with nuts
Number of subjects: 870
Study 28143667 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 870
Study 28143667 — intervention group
Group type: COMPARATOR
Intervention: Total and common olive oil consumption
Number of subjects: 870
Study 27825327 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 207
Study 27825327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 207
Study 27825327 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 207
Study 24739452 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-year, class-based curriculum intervention (22 classroom lessons)
Number of subjects: 100
Study 24739452 — intervention group
Group type: COMPARATOR
Intervention: Existing educational course regarding smoking
Number of subjects: 100
Study 22269076 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered stress management training (SSMT)
Number of subjects: 220
Study 22269076 — intervention group
Group type: COMPARATOR
Intervention: Usual psychosocial care only
Number of subjects: 220
Study 20028830 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Reinforcement (full dose 25% to 50% of the time, placebo other times)
Number of subjects: 46
Study 20028830 — intervention group
Group type: COMPARATOR
Intervention: Dose Control (continuous reinforcement with 25% to 50% of the initial dose)
Number of subjects: 46
Study 20028830 — intervention group
Group type: COMPARATOR
Intervention: Standard Therapy (active drug every treatment with 100% of the initial dose)
Number of subjects: 46
Study 20028830 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Reinforcement
Number of subjects: 46
Study 20028830 — intervention group
Group type: COMPARATOR
Intervention: Dose Control
Number of subjects: 46
Study 20028830 — intervention group
Group type: COMPARATOR
Intervention: Standard Therapy
Number of subjects: 46
Study 18400458 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal ports with topical anesthetic
Number of subjects: 55
Study 18400458 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral access via venipuncture
Number of subjects: 55
Study 18400458 — intervention group
Group type: COMPARATOR
Intervention: External line access
Number of subjects: 55
Study 16258594 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline 5 ml (Group A)
Number of subjects: 150
Study 16258594 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg + dexamethasone 8 mg (Group B)
Number of subjects: 150
Study 16258594 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg + droperidol 1.25 mg (Group C)
Number of subjects: 150
Study 16258594 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg (Group D)
Number of subjects: 150
Study 16258594 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg (Group E)
Number of subjects: 150
Study 12069361 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (average 6.4 +/- 0.7 METs), exercised three times per week for 12 weeks
Number of subjects: 23
Study 12069361 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 23
Study 10400032 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic vascular exclusion with preservation of the caval flow (HVEPC)
Number of subjects: 40
Study 7781632 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia (38.4 mg hyperbaric lignocaine 5%)
Number of subjects: 108
Study 7781632 — intervention group
Group type: COMPARATOR
Intervention: Single-dose spinal anaesthesia (10.8 mg hyperbaric bupivacaine 0.5%)
Number of subjects: 108
Study 7781632 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia
Number of subjects: 108
Study 7781632 — intervention group
Group type: COMPARATOR
Intervention: Single-dose spinal anaesthesia
Number of subjects: 108
Study 2184186 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-focused health care, education about dementia and caregiving, assistance with problem solving, regularly scheduled in-home respite, and a self-help family caregiver support group.
Number of subjects: 60